Pernicious anemia is caused by an autoimmune attack on the stomach lining that destroys the cells responsible for producing intrinsic factor, a protein your body needs to absorb vitamin B12. Without intrinsic factor, B12 from food passes through your digestive tract without ever reaching your bloodstream, eventually leading to a deficiency severe enough to impair red blood cell production and nerve function.
How the Immune System Attacks Your Stomach
The root cause of pernicious anemia is autoimmune gastritis, a condition where your immune system mistakenly targets the parietal cells in your stomach lining. These parietal cells have two critical jobs: they produce stomach acid and they secrete intrinsic factor. In pernicious anemia, the immune system generates antibodies against a specific protein on parietal cells called the proton pump (the same pump that acid-blocking medications target). These antibodies mark the cells for destruction.
The damage unfolds through a specific chain of events. Immune cells, particularly two types of helper T cells (Th1 and Th17), infiltrate the stomach lining and release inflammatory signaling molecules. One of these, called IL-17A, directly triggers parietal cells to self-destruct through a process called apoptosis. Over time, the native glands in the stomach’s main body thin out and disappear, a change called gastric atrophy. As parietal cells are progressively lost, intrinsic factor production drops until there simply isn’t enough to support B12 absorption.
Roughly 85 to 90% of people with autoimmune gastritis test positive for parietal cell antibodies. A separate antibody, anti-intrinsic factor antibody, is more specific to pernicious anemia itself and is detected in about 90% of confirmed cases.
Why Intrinsic Factor Matters So Much
Vitamin B12 can’t cross the intestinal wall on its own. It needs a chaperone. In a healthy stomach, intrinsic factor binds to B12 after the vitamin is released from food by stomach acid. This intrinsic factor-B12 complex then travels to the final section of the small intestine (the ileum), where specialized receptors recognize the complex and pull B12 into the bloodstream.
When parietal cells are destroyed, both halves of this process break down. Less stomach acid means B12 isn’t properly freed from food proteins, and less intrinsic factor means whatever B12 does get released has no way to be absorbed. This is why pernicious anemia can’t be corrected by simply eating more B12-rich foods. The absorption machinery itself is broken.
Genetic Predisposition
Pernicious anemia runs in families, and several genetic markers help explain why. A large genome-wide association study identified a key risk region on chromosome 6, within the HLA complex, the stretch of DNA that shapes how your immune system distinguishes your own tissues from foreign invaders. Specific HLA variants, including HLA-DQB1*06:02 and HLA-DRB1*15:01, were each associated with roughly a 50 to 60% increased odds of developing pernicious anemia.
Earlier research found that the specific HLA pattern varies depending on whether pernicious anemia occurs alongside other autoimmune conditions. Patients who also had autoimmune endocrine diseases (like thyroid disorders or type 1 diabetes) showed different HLA markers than those with pernicious anemia alone. Among patients without endocrine disease, those with the most severe B12 malabsorption, including people who had developed nerve damage, carried certain HLA types at the highest rates. In short, your genetic blueprint influences not just whether you develop pernicious anemia but potentially how severe it becomes.
The H. Pylori Connection
There is growing evidence that infection with Helicobacter pylori, the bacterium best known for causing stomach ulcers, may act as a trigger for autoimmune gastritis in some people. The leading theory involves molecular mimicry: certain proteins on the surface of H. pylori bacteria structurally resemble the proton pump protein on parietal cells. When the immune system mounts a defense against H. pylori, it may accidentally generate antibodies that also attack parietal cells.
One study from Japan found that nearly 20% of patients referred for H. pylori treatment met the criteria for autoimmune gastritis. Many of these patients had already undergone multiple rounds of antibiotic treatment for H. pylori, suggesting the autoimmune process had been set in motion long before diagnosis. This doesn’t mean every H. pylori infection leads to pernicious anemia. Most don’t. But in genetically susceptible people, the infection may be the environmental spark that kicks off the autoimmune cascade.
The two forms of atrophic gastritis, one driven by H. pylori and one driven by autoimmunity, look different under a microscope. Autoimmune gastritis targets the body (corpus) of the stomach while sparing the lower section (antrum), at least in early stages. H. pylori gastritis tends to affect the antrum first. When both conditions overlap, distinguishing them becomes harder.
How It’s Treated
Because the problem in pernicious anemia is absorption rather than intake, treatment bypasses the gut entirely. The standard approach is B12 injections, typically given weekly for the first four weeks to replenish depleted stores, then once monthly for life. The monthly maintenance dose replaces what the body can no longer absorb on its own. Since the underlying autoimmune damage to the stomach lining is permanent in most cases, stopping injections leads to deficiency again.
Some people notice improvements in fatigue and mental clarity within days of starting injections. Neurological symptoms like numbness or balance problems may take weeks to months to improve, and in cases where nerve damage has been present for a long time, some symptoms may not fully reverse.
Long-Term Stomach Cancer Risk
The chronic inflammation and atrophy caused by autoimmune gastritis don’t just affect B12 levels. They also change the stomach lining in ways that raise cancer risk over time. A large study of older adults in the U.S. found that people with pernicious anemia had roughly double the risk of a common type of stomach cancer (non-cardia gastric adenocarcinoma) compared to people without the condition. Even more striking, the risk of gastric carcinoid tumors, a less common type that grows from hormone-producing cells, was 11 times higher. This elevated carcinoid risk persisted and actually grew stronger more than six years after diagnosis.
This is why many gastroenterologists recommend periodic endoscopic monitoring for people with confirmed autoimmune gastritis. The absolute risk of any individual developing stomach cancer remains relatively low, but the relative increase is significant enough to warrant surveillance, particularly in people who have had the condition for many years.